Member Info for ForFXSake

You'll be lucky there.

CB is the Chairman of the BoD, voted in to look after investors interests by gauging the performance of the executives of the company (headed by the CEO)

The Chairman can get rid of the CEO (as we may have already witnessed in June). I don't think it works the other way round.

It could actually be an easier way to gain access tk the market.

Perhaps health authorities are more receptive to considering treatments that offer additional benefits to an existing treatment. No one's nose gets put out of place then, so to speak

I thought this was an interesting part of the statement:

"..since likely adoption of new therapies for IPF will be on top of current standard of care."

That sounds as though they have it on good authority that the current treatments will not be replaced regardless of what comes along. It is as if they been advised that it would be better to push it as a supplementary treatment rather than primary.

That can only apply to a limited target market though (e.g. Japan or UK etc). Is there a current standard of care that is the same in every global.market?

Soup, yes they did. We don't really hear mention of "advanced" negotiations in recent updates though. We just hear that, due to their size, they have little control over the pace of negotiations. That suggests to me that something has gone sour with the advanced partner. I'm not sure what that is It could be that the partner lost confidence due to internal stresses at NFX, or it could be that those stresses arose as the result of the partner not playing ball. Maybe covid resulted in NFX trying to negotiate better terms and that soured things . I don't really know what has happened but the boardroom departures along with the fact that the deal is still not closed after so long suggests that something is not right.

So the fact that the company says that it is still in negotiations doesn't mean that they are still talking to that advanced partner and that the deal is going to drop anytime soon. They may actually be in the early stages of discussing a completely different terms with someone else.

Something doesn't sit right with the NXP002 deal. We've had pre-mature, financially detailed press releases, delayed dealing notifications, a boardroom massacre, 12 months of little apparent progress blamed "in part" on covid and then the CEO left. The company has been vague with its explanations/reassurances so we can only speculate as to what is really going on behind the scenes.

Maybe it's possible that they were in contact with more than one potential partner regarding an Asian deal. Even if the most advanced one pulled out you could still be in a position where, technically, you were still negotiating. Things would have taken a step back though.

How far is 650k (before expenses) really going go in terms of pipeline development plus the salaries of a new CEO and NE director?

I see we've dropped again slightly this morning on pretty much FA volume: 3.2/3.4 500k traded.

I did pose that theory myself a short while ago SSM. However, I argued it was unlikely due to the fact that if his departure was planned and agreed with NFX then they would have issued a press release to that effect in order to avoid any negative speculation which would adversely affect the share price.

Given the current price and departure of DG, I cannot see how a deal for NXP002 could still be on the cards. Particularly one that would re-rate us to 20p+ (as many here seem to expect) and which would leave NFX as an independent company. Its too cheap to simply not take out at a much lower price if it has something that large pharma desires.

"I wouldn't want to be out of this over the weekend LOL"

I've been saying that to myself every Friday afternoon since I bought in last year. Ah well, I suppose one more won't hurt....but I'm definitely cancelling my subscription to The Times next week.

Unfortunately it is sometimes the case that a large partner might insist that price information remains undisclosed until a product gets approved or approaches market release. I have held shares in another bio which signed a few deals with large partners for undisclosed milestones and vague royalties. It is very frustrating as they appear to be substantial deals but so little financial detail is offered by the RNS that the market struggles to value them properly and therefore remains sceptical. Price gains can be very muted as a result.

We need another 1m buy.

Still trying to convince myself that that was more than just a risky punt. Another one should remove any doubts :0)

Is DT still there?

I was joking, Soup

Well found SoupDragon.

I have to say I did a lengthy search through their website and couldn't find anything. They really need to simplify their web content, its a nightmare to trawl through!

Which month?

Maybe by proving that they can now keep a secret (by not leaking news before the event) future partners might be more willing trust us as reliable partners

I don't think that's why the price has fallen.

I simply think there is an exodus of holders ducked in by the P&D's who probably bought in on the expectation of big NXP002 or NXP004 news. NXP001 news is not the big deal they wanted to hear and they probably think that's all we're going to get for the time-being.

For the time being, that money will now be placed somewhere else where hopes of a quick return are high.

What this RNS demonstrates though is that the leaks have been sealed and no one will know exactly when news will land from now on.

I think it does.

See cmhininnett post earlier. It contains excerpt from the end of the RNS that states CINV activities continue alongside. So no detrimental impact on using NXP001 for its original purpose if opportunity arises.

cminhinnett,

You're correct. I missed that. Thanks.